Passa al contenuto
Merck

P7791

Prazosin hydrochloride

≥99.0% (HPLC), powder, α1-adrenoceptor antagonist

Sinonimo/i:

1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine hydrochloride, Furazosin hydrochloride

Slide 1 of 1
Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

50 MG

61,40 €

250 MG

248,00 €

1 G

1.210,00 €

61,40 €

Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine in blocco

Informazioni su questo articolo

Formula empirica (notazione di Hill):
C19H21N5O4 · HCl
Numero CAS:
19237-84-4
Peso molecolare:
419.86
NACRES:
NA.77
PubChem Substance ID:
24277793
UNSPSC Code:
12352200
EC Number:
242-903-4
MDL number:
MFCD00058177
Beilstein/REAXYS Number:
4303561

Documenti fondamentali

Visualizza tutta la documentazione

Vai a

Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti

Nome del prodotto

Prazosin hydrochloride, ≥99.0% (HPLC)

InChI key

WFXFYZULCQKPIP-UHFFFAOYSA-N

InChI

1S/C19H21N5O4.ClH/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22);1H

SMILES string

Cl.COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)c4ccco4

assay

≥99.0% (HPLC)

form

powder

solubility

H2O: 0.5 mg/mL
methanol: 6 mg/mL
dilute aqueous acid: insoluble

Quality Level

100

Gene Information

human ... ADRA1A(148), ADRA1B(147), ADRA1D(146)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 4

Questo articolo
1554705P2680000BP399
Prazosin hydrochloride ≥99.0% (HPLC)

Sigma-Aldrich

P7791

Prazosin hydrochloride

Prazosin hydrochloride United States Pharmacopeia (USP) Reference Standard

USP

1554705

Prazosin hydrochloride

Prazosin hydrochloride European Pharmacopoeia (EP) Reference Standard

P2680000

Prazosin hydrochloride

Prazosin hydrochloride British Pharmacopoeia (BP) Reference Standard

BP399

Prazosin hydrochloride

assay

≥99.0% (HPLC)

assay

-

assay

-

assay

-

form

powder

form

-

form

-

form

solid

Quality Level

100

Quality Level

-

Quality Level

-

Quality Level

-

solubility

H2O: 0.5 mg/mL, dilute aqueous acid: insoluble, methanol: 6 mg/mL

solubility

-

solubility

-

solubility

-

Gene Information

human ... ADRA1A(148), ADRA1B(147), ADRA1D(146)

Gene Information

human ... ADRA1A(148), ADRA1B(147), ADRA1D(146)

Gene Information

human ... ADRA1A(148), ADRA1B(147), ADRA1D(146)

Gene Information

human ... ADRA1A(148), ADRA1B(147), ADRA1D(146)

Application

Prazosin hydrochloride has been used:
  • to block the α1adrenergic receptors that mediate sympathetic vasoconstriction in mice[1]
  • as an α1-adrenoceptor blocker,administered intragastrically in rats[2]
  • as a vasodilator,administered together with inuslin into the left ventricle of mice for the assessment of its effects on renal functions[3]

Biochem/physiol Actions

Peripheral α1-adrenoceptor antagonist; vasodilator. Prazosin can be used to treat chronic posttraumatic stress disorder (PTSD).[4] It plays a role in reducing blood pressure by relaxing blood vessels, hence used in the treatment of high blood pressure.[5]

Disclaimer

Hygroscopic; light sensitive.

Features and Benefits

This compound is a featured product for ADME Tox and Neuroscience research. Discover more featured ADME Tox and Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the α1-Adrenoceptors, α2-Adrenoceptors and Melatonin Receptors pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

General description

Prazosin is a member of the class of α-adrenergic blockers.[5] It is considered as a peripheral vasodilator antihypertensive agent. Prazosin is a derivative of quinazoline.[6]

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

Hazard Classifications

Repr. 2 - STOT RE 2 - STOT SE 3

target_organs

Central nervous system

Classe di stoccaggio

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
BCCN3705
BCCM1863
BCCK9075
BCCG6847
BCCD7612

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Stal Saurav Shrestha et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 55(1), 141-146 (2014-01-05)
The PET radioligand (11)C-CUMI-101 was previously suggested as a putative agonist radioligand for the serotonin 1A (5-hydroxytryptamine 1A [5-HT1A]) receptor in recombinant cells expressing human 5-HT1A receptor. However, a recent study showed that CUMI-101 behaved as a potent 5-HT1A receptor
Enhanced salt sensitivity following shRNA silencing of neuronal TRPV1 in rat spinal cord
Yu S Q and Wang D H
Acta Pharmacologica Sinica, 32(6), 845-845 (2011)
Murray A Raskind et al.
The American journal of psychiatry, 170(9), 1003-1010 (2013-07-13)
The authors conducted a 15-week randomized controlled trial of the alpha-1 adrenoreceptor antagonist prazosin for combat trauma nightmares, sleep quality, global function, and overall symptoms in active-duty soldiers with posttraumatic stress disorder (PTSD) returned from combat deployments to Iraq and
Haptoglobin reduces renal oxidative DNA and tissue damage during phenylhydrazine-induced hemolysis
Lim Y K, et al.
Kidney International, 58(3), 1033-1044 (2000)
Nia C S Lewis et al.
American journal of physiology. Regulatory, integrative and comparative physiology, 304(2), R147-R154 (2012-11-24)
We examined the hypothesis that α(1)-adrenergic blockade would lead to an inability to correct initial orthostatic hypotension (IOH) and cerebral hypoperfusion, leading to symptoms of presyncope. Twelve normotensive humans (aged 25 ± 1 yr; means ± SE) attempted to complete
Visualizza tutti i documenti correlati

Articoli

Receptor Agonists and Antagonists

Gain a deeper understanding of the various types of receptor agonists and antagonists, including full, partial, and inverse agonists and competitive/reversible and non-competitive/irreversible antagonists.

α2-Adrenoceptors

Learn about alpha-2 adrenoceptor and its subtypes, mediated responses, and applications of agonists. Included is a list of available products and a comparison table.

Discover Bioactive Small Molecules for ADME/Tox

Discover Bioactive Small Molecules for ADME/Tox

α1-Adrenoceptor Characteristics and Modulators

Review alpha 1 adrenoceptors as well as their agonists, antagonists, and tissue expression patterns. We suggest several modulators and alternatives for working with a-1 adrenoreceptors.

Vedi tutto

Contenuto correlato

Product Information Sheet - P7791

Product Information Sheet

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica